Article
Cardiac & Cardiovascular Systems
Florian Posch, Tobias Niedrist, Theresa Glantschnig, Saskia Firla, Florian Moik, Ewald Kolesnik, Markus Wallner, Nicolas Verheyen, Philipp J. Jost, Andreas Zirlik, Martin Pichler, Marija Balic, Peter P. Rainer
Summary: Monitoring LVEF, hs-cTnT, and NT-proBNP is useful for dynamic assessment of cardiotoxicity risk in women with HER2+ early breast cancer. Pre-treatment LVEF strongly predicts cardiotoxicity, while longitudinal LVEF trajectory can identify high-risk patients dynamically.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Oncology
Nathalie Bouwer, Tessa G. Steenbruggen, Hanah N. Rier, Jos J. E. M. Kitzen, Carolien H. Smorenburg, Marlies L. van Bekkum, Paul C. de Jong, Jan C. Drooger, Cynthia Holterhues, Marcel J. M. Kofflard, Eric Boersma, Gabe S. Sonke, Mark-David Levin, Agnes Jager
Summary: This study investigated the impact of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer. The findings showed that despite having a reduced baseline left ventricular ejection fraction, 65% of patients did not develop severe cardiotoxicity during an 18-month follow-up. If severe cardiotoxicity did occur, it was partly reversible in more than two-thirds of the cases.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Review
Cardiac & Cardiovascular Systems
Prajith Jeyaprakash, Sukhmandeep Sangha, Katherine Ellenberger, Shanthosh Sivapathan, Faraz Pathan, Kazuaki Negishi
Summary: The study found that the impact of anthracyclines on patients' heart function was less than previously described with modern dosing regimens. This may improve the statistical accuracy for future clinical trials assessing the role of cardioprotective therapy.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Cardiac & Cardiovascular Systems
Iwan Harries, Bostjan Berlot, Natasha Ffrench-Constant, Matthew Williams, Kate Liang, Estefania De Garate, Anna Baritussio, Giovanni Biglino, Juan Carlos Plana, Chiara Bucciarelli-Ducci
Summary: Cancer survivors treated with anthracyclines exhibit significant abnormalities in cardiac structure and function, including smaller left ventricular mass, myocardial cell volume, and signs of myocardial fibrosis, despite having normal left ventricular ejection fraction. This study suggests that cardiovascular magnetic resonance imaging can help identify these abnormalities in cancer survivors with normal LVEF.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Alan Rozanski, Robert J. H. Miller, Heidi Gransar, Donghee Han, Piotr Slomka, Damini Dey, Sean W. Hayes, John D. Friedman, Louise Thomson, Daniel S. Berman
Summary: This study evaluated the relationship between stress-induced myocardial ischemia, revascularization, and all-cause mortality, and found that early myocardial revascularization was associated with a significant reduction in mortality among patients with inducible myocardial ischemia.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Sebastian Rosch, Karl-Patrik Kresoja, Christian Besler, Karl Fengler, Anne Rebecca Schoeber, Maximilian von Roeder, Christian Luecke, Matthias Gutberlet, Karin Klingel, Holger Thiele, Karl-Philipp Rommel, Philipp Lurz
Summary: In this study, patients with heart failure with preserved ejection fraction (HFpEF) were stratified based on left ventricular ejection fraction (LVEF), resulting in distinct morphologic and pathophysiologic subphenotypes. Patients with LVEF ranging from 50% to 60% demonstrated reduced contractility, impaired ventriculo-arterial coupling, and higher extracellular volume fraction, while patients with LVEF >60% exhibited a hypercontractile state with excessive left ventricular afterload and diminished preload reserve.
Article
Cardiac & Cardiovascular Systems
Xinxin Zhang, Yuxi Sun, Yanli Zhang, Feifei Chen, Shuyuan Zhang, Hongyan He, Shuang Song, Gary Tse, Ying Liu
Summary: This study found that HFmrEF patients are heterogeneous with three different subsets identified, each with different outcomes. The association between change in LVEF and adverse outcomes remained significant even after fully adjusting for all-cause mortality and composite outcome. Strategies for managing HFmrEF should include previously measured LVEF to allow stratification based on direction changes in LVEF for better treatment optimization.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Computer Science, Information Systems
Mohanad Alkhodari, Herbert F. Jelinek, Shiza Saleem, Leontios J. Hadjileontiadis, Ahsan H. Khandoker
Summary: This study aimed to investigate the ability of heart rate variability (HRV) in categorizing CAD patients into multiple LVEF groups, based on optimizing indices extracted from HRV data to form HFpEF, HFmEF, and HFrEF categories. The findings showed that HRVEF groups exhibited consistent patterns throughout the diurnal cycle, with various HRV indices playing significant roles in differentiating between HRVEF groups at different time periods.
Article
Biology
David Zahler, Joshua H. Arnold, Tali Bar-On, Ari Raphael, Shafik Khoury, Zach Rozenbaum, Shmuel Banai, Yaron Arbel, Yan Topilsky, Michal Laufer-Perl
Summary: ANT therapy is associated with the development of new valvular diseases, mainly mitral regurgitation, which highlights the importance of monitoring valve function in breast cancer patients.
Article
Medicine, General & Internal
Raluca Mincu, Lena F. Lampe, Amir A. Mahabadi, Rainer Kimmig, Tienush Rassaf, Matthias Totzeck
Summary: Anthracycline-based chemotherapy has a modest impact on diastolic function in breast cancer patients, without altering early diastolic function diagnostic parameters. Further randomized, large-sample studies are needed to clarify the role of diastolic dysfunction in the early diagnosis of anthracycline-induced cardiotoxicity.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Andrzej Minczykowski, Marcin Zwanzig, Mateusz Dziarmaga, Agnieszka Rutkowska, Marek Balinski, Tomasz Krauze, Przemyslaw Guzik, Andrzej Wykretowicz
Summary: Left ventricular systolic function can be assessed using echocardiography with parameters such as LV ejection fraction (LVEF) or global longitudinal peak systolic strain (GLPSS). Newer indices, including global wasted work (GWW), global work efficiency (GWE), and first-phase ejection fraction (LVEF-1), were examined in healthy individuals and patients with stable coronary artery disease (CAD). The results showed that CAD patients had similar LVEF but higher GLPSS and GWW, and lower GWE and LVEF-1 compared to healthy individuals. LVEF-1 was found to have the highest diagnostic accuracy for detecting CAD.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Cardiac & Cardiovascular Systems
Brian P. Halliday, Roxy Senior, Dudley J. Pennell
Summary: The measurement of left ventricular ejection fraction (LVEF) has been a key component in imaging studies for cardiac patients, but its utility as a prognostic indicator has diminished in certain populations such as heart failure patients with preserved ejection fraction (HF-PEF) and those with valvular heart disease. Assessing myocardial strain, particularly global longitudinal strain (GLS), holds promise in improving risk stratification and therapy selection for these patients. Additional studies are needed to fully integrate GLS into routine clinical practice and improve patient outcomes.
EUROPEAN HEART JOURNAL
(2021)
Review
Cardiac & Cardiovascular Systems
Brian P. Halliday, Roxy Senior, Dudley J. Pennell
Summary: Traditional methods of assessing cardiac function like LVEF are no longer accurate in predicting prognosis for heart failure patients, highlighting the need for better indicators such as GLS to improve risk stratification and accuracy of disease assessment. For patients with heart failure and valvular heart disease, GLS may be a superior option to consider.
EUROPEAN HEART JOURNAL
(2021)
Article
Integrative & Complementary Medicine
Shengnan Lu, Yue Sun, Qiang Li, Ying Liu, Hongxia Cui, Xiao Liang
Summary: The study explored the use of 3-dimensional speckle-tracking echocardiography (3DSTE) to evaluate changes in left ventricular function in breast cancer patients after anthracycline chemotherapy. It collected clinical data of 30 patients from December 2020 to December 2022 and performed conventional ultrasonography, routine echocardiography, and 3DSTE to obtain parameters. The results showed that the parameters measured by 3DSTE decreased with an increased cumulative dose of anthracycline drugs, and the myocardial comprehensive index (MCI) was the most sensitive observation index. Serum cardiac troponin T (cTnT) concentrations differed at different chemotherapy time points. The MCI had the highest area under the curve value in receiver operating characteristic curve analysis.
ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE
(2023)
Article
Medicine, General & Internal
Jason Stencel, Hamid R. Alai, Aneesh Dhore-patil, Daniela Urina-Jassir, Thierry H. Le Jemtel
Summary: Preserved ejection fraction heart failure in obese individuals has become common in clinical practice due to the obesity epidemic. It is challenging to determine if obesity enables the development of preserved ejection fraction heart failure or if it is a convergence of two prevalent conditions. However, the obese phenotype of preserved ejection fraction heart failure provides an opportunity to study the effects of bariatric surgery on reversing left ventricular remodeling.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Patricia Altea-Manzano, Ginevra Doglioni, Yawen Liu, Alejandro M. Cuadros, Emma Nolan, Juan Fernandez-Garcia, Qi Wu, Melanie Planque, Kathrin Julia Laue, Florencia Cidre-Aranaz, Xiao-Zheng Liu, Oskar Marin-Bejar, Joke Van Elsen, Ines Vermeire, Dorien Broekaert, Sofie Demeyer, Xander Spotbeen, Jakub Idkowiak, Aurelie Montagne, Margherita Demicco, H. Furkan Alkan, Nick Rabas, Carla Riera-Domingo, Francois Richard, Tatjana Geukens, Maxim De Schepper, Sophia Leduc, Sigrid Hatse, Yentl Lambrechts, Emily Jane Kay, Sergio Lilla, Alisa Alekseenko, Vincent Geldhof, Bram Boeckx, Celia de la Calle Arregui, Giuseppe Floris, Johannes V. Swinnen, Jean-Christophe Marine, Diether Lambrechts, Vicent Pelechano, Massimiliano Mazzone, Sara Zanivan, Jan Cools, Hans Wildiers, Veronique Baud, Thomas G. P. Gruenewald, Uri Ben-David, Christine Desmedt, Ilaria Malanchi, Sarah-Maria Fendt
Summary: The formation of pre-metastatic niche and high-fat diet can increase palmitate availability in future organs of metastases, promoting NF-kappa B acetylation and inducing metastatic signaling. Deletion of acetyltransferase and palmitoyltransferase reduces metastasis formation.
Article
Oncology
N. Colombo, A. Gadducci, J. Sehouli, E. Rulli, J. Maeenpaeae, C. Sessa, A. Montes, N. B. Ottevanger, R. Berger, I. Vergote, M. B. D'Incalci, C. Churruca Galaz, R. Chekerov, G. B. Nyvang, S. Riniker, R. Herbertson, R. Fossati, M. P. Barretina-Ginesta, M. Deryal, M. R. Mirza, E. Biagioli, M. Iglesias, G. Funari, M. Romeo, G. Tasca, B. Pardo, G. Tognon, M. J. Rubio-Perez, A. DeCensi, U. De Giorgi, P. Zola, P. Benedetti Panici, M. Aglietta, V. Arcangeli, C. Zamagni, A. Bologna, A. Westermann, V. Heinzelmann-Schwarz, I. Tsibulak, P. Wimberger, A. Poveda
Summary: This trial aimed to investigate whether treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients with recurrent ovarian cancer (OC). The results showed that TP did not significantly improve OS in patients with a TFIp of 6-12 months, but it remains an effective treatment for patients suffering from persistent platinum toxicities.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Elien Heylen, Paulien Verstraete, Linde Van Aerschot, Shauni L. Geeraerts, Tom Venken, Kalina Timcheva, David Nittner, Jelle Verbeeck, Jonathan Royaert, Marion Gijbels, Anne Uyttebroeck, Heidi Segers, Diether Lambrechts, Jan Cools, Kim De Keersmaecker, Kim R. Kampen
Summary: This study identifies the transcription factor NKX2-1 as a driver of serine/glycine synthesis addiction in cancer cells. NKX2-1 binds and transcriptionally upregulates serine/glycine synthesis enzyme genes, enabling cells expressing NKX2-1 to proliferate and invade in serine/glycine-depleted conditions. The findings reveal the unique metabolic rewiring of NKX2-1-driven cancers and provide possibilities for new therapeutic strategies.
BRITISH JOURNAL OF CANCER
(2023)
Article
Endocrinology & Metabolism
Jonathan Roos, Daniel Schurch, Andreas Frei, Sophie Lagger, Matthias Schwenkglenks, Andreas Vogt, David Herzig, Lia Bally
Summary: A comparison was made between fully automated closed-loop insulin therapy and standard insulin therapy for perioperative glucose management. The study found that closed-loop insulin therapy reduced the time required for glucose management compared to standard insulin therapy, across different perioperative care periods.
Article
Geriatrics & Gerontology
Francois-Xavier Sibille, Marie de Saint-Hubert, Severine Henrard, Carole Elodie Aubert, Namiko Anna Goto, Emma Jennings, Olivia Dalleur, Nicolas Rodondi, Wilma Knol, Denis O'Mahony, Matthias Schwenkglenks, Anne Spinewine
Summary: This study analyzed the use of benzodiazepine receptor agonists (BZRAs) in middle-aged adults and investigated the rate of BZRA cessation during and after hospitalization. The results showed that nearly a quarter of BZRA users successfully ceased BZRA within 6 months after hospitalization. Therefore, targeted BZRA deprescribing programs could enhance cessation, while specific attention is needed for females, central nervous system-acting co-medication, and comorbidity with chronic obstructive pulmonary disease (COPD).
Article
Oncology
Antonio Gonzalez-Martin, Bhavana Pothuri, Ignace Vergote, Whitney Graybill, Domenica Lorusso, Colleen C. McCormick, Gilles Freyer, Floor Backes, Florian Heitz, Andres Redondo, Richard G. Moore, Christof Vulsteke, Roisin E. O'Cearbhaill, Izabela A. Malinowska, Luda Shtessel, Natalie Compton, Mansoor R. Mirza, Bradley J. Monk
Summary: This study reports the long-term efficacy and safety of the PRIMA/ENGOT-OV26/GOG-3012 trial. The results show that niraparib maintains clinically significant improvements in progression-free survival (PFS) in high-risk patients with newly diagnosed advanced ovarian cancer, regardless of HRD status. No new safety signals were identified.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Thomas J. Herzog, Sandro Pignata, Sharad A. Ghamande, Maria-Jesus Rubio, Keiichi Fujiwara, Christof Vulsteke, Deborah K. Armstrong, Jalid Sehouli, Robert L. Coleman, Hani Gabra, Giovanni Scambia, Bradley J. Monk, Jose A. Arranz, Kimio Ushijima, Rabbie Hanna, Claudio Zamagni, Robert M. Wenham, Antionio Gonzalez-Martin, Brian Slomovitz, Yan Jia, Lisa Ramsay, Krishnansu S. Tewari, Susan C. Weil, Ignace B. Vergote
Summary: The study aimed to determine the efficacy of farletuzumab, an antifolate receptor-alpha monoclonal antibody, in improving progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer. The results showed that adding farletuzumab did not improve PFS, and the expression of the folate receptor-alpha was not measured in this study.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
J. E. Rosenberg, T. Powles, G. P. Sonpavde, Y. Loriot, I. Duran, J. -L. Lee, N. Matsubara, C. Vulsteke, D. Castellano, R. Mamtani, C. Wu, M. Matsangou, M. Campbell, D. P. Petrylak
Summary: This study evaluated the efficacy and safety of Enfortumab Vedotin compared to chemotherapy in patients with advanced urothelial carcinoma. The results showed that Enfortumab Vedotin had a significant improvement in overall survival and progression-free survival, and the adverse events were manageable.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Hanne Lefrere, Kat Moore, Giuseppe Floris, Joyce Sanders, Iris M. Seignette, Tycho Bismeijer, Dennis Peters, Annegien Broeks, Erik Hooijberg, Kristel Van Calsteren, Patrick Neven, Ellen Warner, Fedro Alessandro Peccatori, Sibylle Loibl, Charlotte Maggen, Sileny N. Han, Katarzyna J. Jerzak, Daniela Annibali, Diether Lambrechts, Karin E. de Visser, Lodewyk Wessels, Liesbeth Lenaerts, Frederic Amant
Summary: Patients with postweaning postpartum breast cancer (PP-BCPW) have a poor prognosis compared with other types of breast cancer. This study found that PP-BCPW patients with low expression of immunoglobulin genes but high infiltration of plasma B cells have an increased risk of metastasis and death.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Liselore Loverix, Ignace Vergote, Pieter Busschaert, Adriaan Vanderstichele, Tom Venken, Bram Boeckx, Philipp Harter, Hilde Brems, Els Van Nieuwenhuysen, Sandro Pignata, Thais Baert, Antonio Gonzalez-Martin, Sileny Han, Christian Marth, Patrick Neven, Nicoletta Colombo, Patrick Berteloot, Johanna Maeenpaeae, Siel Olbrecht, Tina Laga, Erwin Sablon, Isabelle Ray-Coquard, Eric Pujade-Lauraine, Diether Lambrechts, Toon Van Gorp
Summary: The Leuven HRD test and Myriad HRD test have similar predictive value for PFS and OS in HRD+ patients, and there is a robust correlation between the two tests.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
Nicola Julia Aebi, Iris Baenteli, Gunther Fink, Gunther Meinlschmidt, Rainer Schaefert, Matthias Schwenkglenks, Anja Studer, Sarah Trost, Sibil Tschudin, Kaspar Wyss, SomPsyNet Consortium
Summary: Implementing psychosocial distress assessments in a hospital setting in Switzerland faces challenges, but regular training, feedback, and collaboration with experts can support successful implementation.
Article
Cell Biology
Stefan Naulaerts, Angeliki Datsi, Daniel M. Borras, Asier Antoranz Martinez, Julie Messiaen, Isaure Vanmeerbeek, Jenny Sprooten, Raquel S. Laureano, Jannes Govaerts, Dena Panovska, Marleen Derweduwe, Michael C. Sabel, Marion Rapp, Weiming Ni, Sean Mackay, Yannick Van Herck, Lendert Gelens, Tom Venken, Sanket More, Oliver Bechter, Gabriele Bergers, Adrian Liston, Steven De Vleeschouwer, Benoit J. Van Den Eynde, Diether Lambrechts, Michiel Verfaillie, Francesca Bosisio, Sabine Tejpar, Jannie Borst, Rudiger V. Sorg, Frederik De Smet, Abhishek D. Garg
Summary: Through multiomics analysis of CD8+ T cell features in multiple patient cohorts and tumor types, we have identified different hypofunctional states of tumor-associated CD8+ T cells, including exhausted CD8+ T cells in supportive tumor niches and hypofunctional CD8+ T cells in nonsupportive niches. These two types of hypofunctional states exhibit distinct characteristics, such as different T cell receptor repertoires and immunopeptidomes. Furthermore, dysfunctional CD4+:CD8+ T cell interactions and a wound healing-like chemokine profile were observed in glioblastoma. Immuno-oncology clinical trials showed that anti-programmed cell death protein 1 (PD-1) immunotherapy exacerbated the tolerogenic disparities in glioblastoma, while dendritic cell (DC) vaccines partially corrected them. Recipients of DC vaccines for glioblastoma demonstrated evidence of antigen-specific immunity.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Meeting Abstract
Oncology
P. T. L. Van Mol, A. Franken, S. Vanmassenhove, E. Donders, R. Schepers, T. Van Brussel, C. Dooms, J. Yserbyt, N. De Crem, D. Testelmans, W. de wever, K. L. Nackaerts, J. F. Vansteenkiste, R. Vos, D. Lambrechts, J. Naidoo, K. Suresh, S. Humblet-Baron, E. Wauters
JOURNAL OF THORACIC ONCOLOGY
(2023)
Meeting Abstract
Urology & Nephrology
L. Elst, G. Philips, B. Boeckx, R. Schepers, T. Van Brussel, M. Baldewijns, A-S Van Rompuy, D. Lambrechts, M. Albersen
Article
Oncology
Szymon Macioszek, Danuta Dudzik, Rafal Bartoszewski, Tomasz Stokowy, Diether Lambrechts, Bram Boeckx, Agnieszka Wozniak, Patrick Schoffski, Michal J. Markuszewski
Summary: In this study, integrative metabolomic and transcriptomic analyses were performed to investigate the impact of imatinib treatment on tumour biochemical processes. The results revealed differential metabolite and gene expression profiles, indicating changes in pruine and pyrinridine metabolism, butanoate metabolism, as well as alanine, aspartate, and glutamate metabolism. These findings provide insights into the mechanisms of imatinib's anti-tumour activity and suggest a potentially novel approach for enhancing its efficacy or re-sensitizing imatinib-resistant tumours.
TRANSLATIONAL ONCOLOGY
(2023)